Eledon Pharmaceuticals, Inc. (ELDN) News
Track canonical SquawkNews coverage tagged to ELDN, Eledon Pharmaceuticals, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 6 indexed stories across 4 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Eledon Pharmaceuticals reports Q2 2026 financial results
Eledon Pharmaceuticals (ELDN) reports second-quarter 2026 financial results and recent business highlights.
EARNINGS | Aug 13, 2026, 08:09 PM UTC
L
ELDN new Buy W/ $12 PT @ Rodman
ELDN new Buy W/ $12 PT @ Rodman
EQUITY | Jul 21, 2026, 12:32 PM UTC
L
ELDN Initiated Buy W/$12.00 PT at Rodman & Renshaw
ELDN Initiated Buy W/$12.00 PT at Rodman & Renshaw
EQUITY | Jul 21, 2026, 12:09 PM UTC
L
NewcelX Completes Type B Pre-IND Meeting With FDA; Administration Provided Constructive Feedback And Alignment On Proposed Strategy
The FDA provided clarity regarding the regulatory pathway toward launching a clinical trial of NCEL-101 for type 1 diabetes in combination with Eledon Pharmaceuticals’ (NASDAQ: ELDN ) anti-CD40L antibody, tegoprubart, an
REGULATION | Jul 01, 2026, 01:33 PM UTC
M
ELDN: Presents Kidney Transplant Data
Eledon Pharma presents new long-term data from Phase 2 BESTOW clinical program evaluating Tegoprubart in patients undergoing kidney transplantation at ATC 2026
EQUITY | Jun 22, 2026, 11:20 AM UTC
M
ELDN Presents BESTOW Results
Eledon presents long-term extension phase 2 BESTOW results showing sustained higher kidney function and improved patient-reported outcomes with Tegoprubart compared with Tacrolimus
EQUITY | Jun 22, 2026, 11:01 AM UTC